In addition to launching the new indication, the 0.9 mg tablet strength, approved by FDA in April, will now be added to the existing range of tablet dosing strengths which also includes 0.3 mg, 0.45 mg, 0.625 mg and 1.25 mg dosing strengths. This new dosage strength provides additional options for healthcare professionals and patients initiating oral estrogen therapy. Patients should be started at the lowest approved dose of 0.3 mg of ENJUVIA daily. Subsequent dosage adjustment (which will differ depending on the indication) and periodic reassessment may be made based upon the individual patient response. When prescribed solely for the treatment of symptoms of vulvar and vaginal atrophy, topical products should be considered.
(1) Menopause: The Journal of the North American Menopause Society
Vol. 14, No.3 pp. 357-358
(2) Bachman Ga, Ebert GA, Burd ID. Vulvovaginal Complaints. In: Lobo RA,
ed. Treatment of the Postmenopausal Woman: Basic and Clinical
Aspects. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins;
Menopause is the time in a woman's life when the menstrual period
ceases and the ovaries permanently stop releasing eggs. Menopause is
considered complete when a woman has been without her period for a full
year. While some women experience no menopausal symptoms, others suffer
severe symptoms that require treatment. Vasomotor symptoms (night sweats,
hot flashes) and vaginal symptoms such as vaginal dryness and pain with
intercourse are common menopausal symptoms. Although the majority of women
|SOURCE Barr Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved